Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach.

Cell cycle and apoptosis regulatory proteins are markers of tumor progression in colorectal cancer. In a series of 1,274 mismatch repair-proficient colorectal cancers, immunohistochemical analysis of p21, p27, p53, and bcl-2 expression was performed using the tissue microarray technique. In univariate analysis, p21 expression was associated with tumor location and pN0; p27 expression with tumor location, lower tumor grade, early pT, and pN; p53 expression with tumor location; and bcl-2 with early pT and pN. Expression of p27 identified subgroups with worse prognosis in pT3 N0 and pT3 N+ patients. None of the 4 tumor markers were independent prognostic indicators of survival. The multimarker phenotypes p21/p27/p53 and p21/p27/bcl-2 were associated with survival. In mismatch repair-proficient colorectal cancer, p27 expression is associated with a better prognosis, and pT, pN, and vascular invasion are independent prognostic factors. In addition, multimarker phenotypes are useful to identify colorectal cancer subgroups with different prognoses.

[1]  H. Stein,et al.  Prognostic Value of Multimarker Analysis in Stage III Colorectal Cancer: One Step Forward Towards an Individualized Therapy Decision , 2005, Oncology Research and Treatment.

[2]  F. Bazzoli,et al.  High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies , 2005, Clinical Cancer Research.

[3]  D. Lane,et al.  P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.

[4]  R. Herrmann,et al.  Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Chetty p27 Protein and Cancers of the Gastrointestinal Tract and Liver: An Overview , 2003, Journal of clinical gastroenterology.

[6]  R. Herrmann,et al.  SMAD7 is a prognostic marker in patients with colorectal cancer , 2003, International journal of cancer.

[7]  B. Iacopetta TP53 mutation in colorectal cancer , 2003, Human mutation.

[8]  C. Hsieh,et al.  Molecular lesions in colorectal cancer: impact on prognosis? , 2003, International Journal of Colorectal Disease.

[9]  C. Cordon-Cardo,et al.  Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  B. Leggett,et al.  Emerging concepts in colorectal neoplasia. , 2002, Gastroenterology.

[11]  H. Stein,et al.  Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors , 2002, International journal of cancer.

[12]  H. McLeod,et al.  Analysis of key cell‐cycle checkpoint proteins in colorectal tumours , 2002, The Journal of pathology.

[13]  G. Peters,et al.  Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. , 2002, Journal of clinical pathology.

[14]  U. Manne,et al.  Molecular staging of colorectal cancer in African‐American and Caucasian patients using phenotypic expression of p53, Bcl‐2, MUC‐1 AND p27kip‐1 , 2002, International journal of cancer.

[15]  R. Houlston,et al.  What we could do now: molecular pathology of colorectal cancer , 2001, Molecular pathology : MP.

[16]  P. Maxwell,et al.  Apoptosis and cell‐cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival , 2001, The Journal of pathology.

[17]  H. Zhang,et al.  Loss of p27 expression predicts poor prognosis in patients with Dukes' B stage or proximal colorectal cancer. , 2001, International journal of oncology.

[18]  R. Kolodner,et al.  Multiple pathways cooperate in the suppression of genome instability in Saccharomyces cerevisiae , 2001, Nature.

[19]  Nandita Ghosh,et al.  Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma , 2001, Diseases of the colon and rectum.

[20]  S. Wexner,et al.  Dukes B Colorectal Cancer: Distinct Genetic Categories and Clinical Outcome Based on Proximal or Distal Tumor Location , 2001 .

[21]  R. Kolodner,et al.  Suppression of Spontaneous Chromosomal Rearrangements by S Phase Checkpoint Functions in Saccharomyces cerevisiae , 2001, Cell.

[22]  H. Weiss,et al.  Molecular characterization of colorectal neoplasia in translational research. , 2001, Archives of pathology & laboratory medicine.

[23]  A. Giatromanolaki,et al.  Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse. , 2001, Anticancer research.

[24]  P. Cheah,et al.  Down‐regulation of p27 is a significant predictor of poor overall survival and may facilitate metastasis in colorectal carcinomas , 2000, International journal of cancer.

[25]  J. Nesland,et al.  Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas , 2000, Virchows Archiv.

[26]  H. McLeod,et al.  Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  R. Broll,et al.  p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. , 2000, European journal of cancer.

[28]  S. Baldus,et al.  Prognostic impact of p21/waf1/cip1 in colorectal cancer , 2000, International journal of cancer.

[29]  I. D'Agnano,et al.  Evaluation of multiple bio‐pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl‐2 , 1999, International journal of cancer.

[30]  P. Laurent-Puig,et al.  Sequence of molecular genetic events in colorectal tumorigenesis. , 1999, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[31]  F. Marandino,et al.  Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  A. Cittadini,et al.  Reduced expression and altered subcellular localization of the cyclin‐dependent kinase inhibitor p27Kip1 in human colon cancer , 1999, Molecular carcinogenesis.

[33]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[34]  Parfrey,et al.  bcl‐2 protein expression is associated with better prognosis in colorectal cancer , 1999, Histopathology.

[35]  H. Moch,et al.  Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  G. Landberg,et al.  Prognostic significance of p27Kip1 expression in colorectal cancer: a clinico‐pathological characterization , 1999, The Journal of pathology.

[37]  J. Cheville,et al.  p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.

[38]  G. Viale,et al.  p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations , 1999, The Journal of pathology.

[39]  J. Jass,et al.  Towards a molecular classification of colorectal cancer , 1999, International Journal of Colorectal Disease.

[40]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[41]  M. Loda,et al.  Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. , 1998, The American journal of pathology.

[42]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[43]  M. Loda,et al.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas , 1997, Nature Medicine.

[44]  H. Höfler,et al.  EXPRESSION OF bcl‐2 AND p53 IN DE NOVO AND EX‐ADENOMA COLON CARCINOMA: A COMPARATIVE IMMUNOHISTOCHEMICAL STUDY , 1996, The Journal of pathology.

[45]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[46]  K. Kinzler,et al.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.

[47]  C. Cordon-Cardo Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.

[48]  D. Hicks,et al.  BCL-2 expression in human colorectal adenomas and carcinomas. , 1994, Oncogene.

[49]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[50]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[51]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.